Home » Newsletters » BioWorld Science

BioWorld Science

July 22, 2022

View Archived Issues

NiKang Therapeutics patents new PROTACs for cancer

Genzyme discloses new CSF-1R inhibitors

Gilead Sciences synthesizes new PADI4 inhibitors

University of California presents new CYP3A4 inhibitors

MEKanistic Therapeutics identifies new PI3K and/or EGFR inhibitors

GATA1 c.616A>C mutation tied to thrombocytopenia due to platelet formation impairment

Inosine released by apoptotic brown adipocytes regulates thermogenic fat and counteracts obesity

PAN domain regulates binding and activation of the c-MET pathway and may be an anticancer target

Novel variants in genes HPS3, HPS5 and DTNBP1 linked to Hermansky-Pudlak syndrome

Preclinical characterization of novel antileishmanial agents

PharmaCyte begins pig study to support planned clinical trial of CypCaps for pancreatic cancer

FDA clears IND for Obsidian's TIL therapy OBX-115

Sosei and Cancer Research UK agree to advance EP4 antagonist HTL-0039732 into clinic

Oncogenic collagen allows cancer cells to evade immune response

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 15, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 16, 2025.
Neutrophils put the brakes on fat loss
BioWorld Science
Fat tissue balances energy by storing lipids during times of abundance and mobilizing them when needed, yet sustained metabolic stress demands mechanisms that...
CTAD 2025: Diagnosing semaglutide’s failure in Alzheimer’s trials
BioWorld
A little over a week after announcing that the Evoke and Evoke+ studies failed to show that oral semaglutide could slow cognition decline in patients with...
Peptidream reveals milestone in Alnylam collaboration
BioWorld Science
Peptidream Inc. has announced a preclinical development milestone in its collaboration with Alnylam Pharmaceuticals Inc. under their siRNA conjugate discovery...